ALEXION Pharmaceuticals has announced that the United States Patent and Trademark Office has extended patents for Soliris (eculizumab) to include paroxysmal nocturnal hemoglobinuria (PNH) with patent expiration in 2027.
The above article was sent to subscribers in Pharmacy Daily's issue from 18 Aug 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 18 Aug 17
